Skip to main content

Rescentris Secures Series A Funding

NEW YORK, May 4 (GenomeWeb News) - Rescentris, a provider of electronic laboratory notebook software, said today that it has completed its Series A financing.


The company did not disclose the amount of funding, but said that it will be used to expand its sales and marketing programs and further development of its flagship product, the Collaborative Electronic Research Framework (CERF).


Initial development of CERF was funded in part by a grant from the State of Ohio's Third Frontier Project, Rescentris said.


The product was developed in collaboration with OhioStateUniversity's BioMedical Informatics department.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.